Levels of soluble Fas/APO-1 in patients with Behçet's disease.

The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quant...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamzaoui, K, Hamzaoui, A, Zakraoui, L, Chabbou, A
Formato: Texto
Lenguaje:English
Publicado: 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781828/
https://www.ncbi.nlm.nih.gov/pubmed/9836498
_version_ 1782131983795617792
author Hamzaoui, K
Hamzaoui, A
Zakraoui, L
Chabbou, A
author_facet Hamzaoui, K
Hamzaoui, A
Zakraoui, L
Chabbou, A
author_sort Hamzaoui, K
collection PubMed
description The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.
format Text
id pubmed-1781828
institution National Center for Biotechnology Information
language English
publishDate 1998
record_format MEDLINE/PubMed
spelling pubmed-17818282007-01-25 Levels of soluble Fas/APO-1 in patients with Behçet's disease. Hamzaoui, K Hamzaoui, A Zakraoui, L Chabbou, A Mediators Inflamm Research Article The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD. 1998 /pmc/articles/PMC1781828/ /pubmed/9836498 Text en
spellingShingle Research Article
Hamzaoui, K
Hamzaoui, A
Zakraoui, L
Chabbou, A
Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title_full Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title_fullStr Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title_full_unstemmed Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title_short Levels of soluble Fas/APO-1 in patients with Behçet's disease.
title_sort levels of soluble fas/apo-1 in patients with behçet's disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781828/
https://www.ncbi.nlm.nih.gov/pubmed/9836498
work_keys_str_mv AT hamzaouik levelsofsolublefasapo1inpatientswithbehcetsdisease
AT hamzaouia levelsofsolublefasapo1inpatientswithbehcetsdisease
AT zakraouil levelsofsolublefasapo1inpatientswithbehcetsdisease
AT chabboua levelsofsolublefasapo1inpatientswithbehcetsdisease

Ejemplares similares